Based on the RENAU.UNSP.ARD 1/5 EO-20 stock forecast from 0 analysts, the average analyst target price for RENAU.UNSP.ARD 1/5 EO-20 is not available over the next 12 months. RENAU.UNSP.ARD 1/5 EO-20’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of RENAU.UNSP.ARD 1/5 EO-20 is Bearish, which is based on 3 positive signals and 8 negative signals. At the last closing, RENAU.UNSP.ARD 1/5 EO-20’s stock price was EUR 18.90. RENAU.UNSP.ARD 1/5 EO-20’s stock price has changed by +11.18% over the past week, +5.59% over the past month and -4.06% over the last year.
No recent analyst target price found for RENAU.UNSP.ARD 1/5 EO-20
No recent average analyst rating found for RENAU.UNSP.ARD 1/5 EO-20
Company Overview RENAU.UNSP.ARD 1/5 EO-20
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG. Read Less
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for ...Read More
Frequently Asked Questions About RENAU.UNSP.ARD 1/5 EO-20 (56S0:F) Stock
Stock Target Advisor's fundamental analysis for RENAU.UNSP.ARD 1/5 EO-20's stock is Bearish.
56S0:F stock's dividend yield is 0.40%.
Our analysis grades 56S0:F stock's dividend yield at F. This means that 56S0:F stock's dividend yield is above 12% of the stocks in the Medical Instruments & Supplies sector in the F exchange.
Based on this 56S0:F may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on 56S0:F's stock to indicate what its average analyst target is.
56S0:F stock's Price/Earning ratio is 102.94.
Our analysis grades 56S0:F stock's Price / Earning ratio at F. This means that 56S0:F stock's Price/Earning ratio is above 80% of the stocks in the Medical Instruments & Supplies sector in the F exchange.
Based on this 56S0:F may be a overvalued for its sector.
The last closing price of 56S0:F's stock was EUR 18.90.
The most recent market capitalization for 56S0:F is EUR 17.62B.
Unfortunately we do not have enough analyst data on 56S0:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains RENAU.UNSP.ARD 1/5 EO-20's stock.
As per our most recent records RENAU.UNSP.ARD 1/5 EO-20 has 10,082 Employees.
RENAU.UNSP.ARD 1/5 EO-20's registered address is Zone Industrielle Les Paluds, Aubagne, France, 13781.
You can get more information about it from RENAU.UNSP.ARD 1/5 EO-20's website at https://www.sartorius.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About RENAU.UNSP.ARD 1/5 EO-20 (56S0:F) Stock
Stock Target Advisor's fundamental analysis for RENAU.UNSP.ARD 1/5 EO-20's stock is Bearish.
56S0:F stock's dividend yield is 0.40%.
Our analysis grades 56S0:F stock's dividend yield at F. This means that 56S0:F stock's dividend yield is above 12% of the stocks in the Medical Instruments & Supplies sector in the F exchange.
Based on this 56S0:F may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on 56S0:F's stock to indicate what its average analyst target is.
56S0:F stock's Price/Earning ratio is 102.94.
Our analysis grades 56S0:F stock's Price / Earning ratio at F. This means that 56S0:F stock's Price/Earning ratio is above 80% of the stocks in the Medical Instruments & Supplies sector in the F exchange.
Based on this 56S0:F may be a overvalued for its sector.
The last closing price of 56S0:F's stock was EUR 18.90.
The most recent market capitalization for 56S0:F is EUR 17.62B.
Unfortunately we do not have enough analyst data on 56S0:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains RENAU.UNSP.ARD 1/5 EO-20's stock.
As per our most recent records RENAU.UNSP.ARD 1/5 EO-20 has 10,082 Employees.
RENAU.UNSP.ARD 1/5 EO-20's registered address is Zone Industrielle Les Paluds, Aubagne, France, 13781.
You can get more information about it from RENAU.UNSP.ARD 1/5 EO-20's website at https://www.sartorius.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 56S0:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
